Position in INAB
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$980,354
-$1,495 QoQ
Shares Held
695,287
+4.8% QoQ
Ownership
7.05%
of shares outstanding
% of Portfolio
0.75%
of 13F equity value
Holder Rank
#4
of 21 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Stonepine Capital Management, LLC holds $108,574,607 across 61 Biotechnology names. INAB ranks #23 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VSTM |
Verastem, Inc.
|
3,349,627 | $12,795,575 | |
| 2 | TENX |
Tenax Therapeutics, Inc.
|
660,000 | $9,603,000 | |
| 3 | NKTR |
Nektar Therapeutics
|
120,654 | $8,422,855 | |
| 4 | ADMA |
Adma Biologics, Inc.
|
740,000 | $6,193,800 | |
| 5 | CAMP |
Camp4 Therapeutics Corp
|
1,389,622 | $6,072,648 | |
| 6 | ELOX |
Eloxx Pharmaceuticals, Inc.
|
397,160 | $5,512,580 | |
| 7 | KZIA |
Kazia Therapeutics Ltd
|
345,179 | $4,860,120 | |
| 8 | CRBP |
Corbus Pharmaceuticals Holdings, Inc.
|
425,000 | $3,986,500 |
All Filings in INAB
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $980,354 | 695,287 | Shares | Sole | 2026-08-17 | |
| 2026-03-31 | $981,849 | 663,412 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $385,849 | 164,893 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $345,943 | 159,421 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $172,278 | 82,430 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||